BIOA - NASDAQ
BioAge Labs, Inc.
$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
At a Glance
Live Snapshotbioa
Total Non-Current Liabilities
Last Annual Value
2.70M
3-Year CAGR
-73%
5-Year CAGR
-54%
10-Year CAGR
-32%
BioAge Labs, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 BioAge Labs, Inc. NASDAQ:BIOA | 2.70M | -73.3% | N/A | N/A | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 0.00 | N/A | N/A | N/A | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 2.88M | 25.5% | N/A | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 16.98M | -8.6% | N/A | N/A | |
 Vor Biopharma Inc. NASDAQ:VOR | 603.27M | 140.2% | 106.2% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 94.89M | -0.5% | -9.1% | N/A | |
 Aclaris Therapeutics, Inc. NASDAQ:ACRS | 28.73M | 45.8% | -1.5% | 54.4% | |
 Atlantic International Corp. NASDAQ:ATLN | 30.37M | 89.6% | N/A | 58.5% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 0.00 | N/A | N/A | N/A | |
 Journey Medical Corporation NASDAQ:DERM | 25.30M | 20.0% | 47.4% | -1.8% | |
 Health Catalyst, Inc. NASDAQ:HCAT | 167.29M | -12.0% | -5.1% | N/A |
BioAge Labs, Inc. Fair Value Envelope
Related Guides
Continue your BIOA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.